Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.17
PKI's Cash to Debt is ranked lower than
52% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. PKI: 0.17 )
PKI' s 10-Year Cash to Debt Range
Min: 0.09   Max: 2.06
Current: 0.17

0.09
2.06
Equity to Asset 0.51
PKI's Equity to Asset is ranked higher than
61% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. PKI: 0.51 )
PKI' s 10-Year Equity to Asset Range
Min: 0.24   Max: 0.63
Current: 0.51

0.24
0.63
Interest Coverage 5.81
PKI's Interest Coverage is ranked higher than
52% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 566.16 vs. PKI: 5.81 )
PKI' s 10-Year Interest Coverage Range
Min: 2.15   Max: 16.75
Current: 5.81

2.15
16.75
F-Score: 5
Z-Score: 3.35
M-Score: -2.63
WACC vs ROIC
3.37%
7.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.69
PKI's Operating margin (%) is ranked higher than
85% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. PKI: 9.69 )
PKI' s 10-Year Operating margin (%) Range
Min: 1.62   Max: 10.86
Current: 9.69

1.62
10.86
Net-margin (%) 7.34
PKI's Net-margin (%) is ranked higher than
87% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. PKI: 7.34 )
PKI' s 10-Year Net-margin (%) Range
Min: -10.1   Max: 22.94
Current: 7.34

-10.1
22.94
ROE (%) 7.99
PKI's ROE (%) is ranked higher than
82% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. PKI: 7.99 )
PKI' s 10-Year ROE (%) Range
Min: -11.62   Max: 32.47
Current: 7.99

-11.62
32.47
ROA (%) 4.11
PKI's ROA (%) is ranked higher than
82% of the 302 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.41 vs. PKI: 4.11 )
PKI' s 10-Year ROA (%) Range
Min: -5.23   Max: 12.48
Current: 4.11

-5.23
12.48
ROC (Joel Greenblatt) (%) 45.86
PKI's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. PKI: 45.86 )
PKI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.35   Max: 69.55
Current: 45.86

4.35
69.55
Revenue Growth (3Y)(%) 5.30
PKI's Revenue Growth (3Y)(%) is ranked higher than
70% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. PKI: 5.30 )
PKI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.7   Max: 17.9
Current: 5.3

-10.7
17.9
EBITDA Growth (3Y)(%) 17.30
PKI's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. PKI: 17.30 )
PKI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20.9   Max: 35.2
Current: 17.3

-20.9
35.2
EPS Growth (3Y)(%) 421.70
PKI's EPS Growth (3Y)(%) is ranked higher than
99% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. PKI: 421.70 )
PKI' s 10-Year EPS Growth (3Y)(%) Range
Min: -79   Max: 421.7
Current: 421.7

-79
421.7
» PKI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PKI Guru Trades in Q2 2014

Joel Greenblatt 55,177 sh (New)
PRIMECAP Management 2,116,374 sh (+0.01%)
Chuck Royce 3,540,320 sh (unchged)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Columbia Wanger 972,000 sh (unchged)
Ken Fisher 607,924 sh (-0.20%)
RS Investment Management 393,864 sh (-19.61%)
Jim Simons 170,800 sh (-46.96%)
» More
Q3 2014

PKI Guru Trades in Q3 2014

Joel Greenblatt 137,475 sh (+149.15%)
PRIMECAP Management 2,254,111 sh (+6.51%)
Ken Fisher 614,529 sh (+1.09%)
Chuck Royce 3,540,320 sh (unchged)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Jim Simons Sold Out
Columbia Wanger Sold Out
RS Investment Management 393,514 sh (-0.09%)
» More
Q4 2014

PKI Guru Trades in Q4 2014

Jim Simons 248,000 sh (New)
Joel Greenblatt 610,891 sh (+344.37%)
PRIMECAP Management 3,260,285 sh (+44.64%)
Vanguard Health Care Fund 1,441,400 sh (unchged)
RS Investment Management Sold Out
Ken Fisher 611,262 sh (-0.53%)
Chuck Royce 2,778,200 sh (-21.53%)
» More
Q1 2015

PKI Guru Trades in Q1 2015

Steven Cohen 18,400 sh (New)
PRIMECAP Management 3,462,295 sh (+6.20%)
Ken Fisher 626,715 sh (+2.53%)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce 2,740,100 sh (-1.37%)
Jim Simons 138,500 sh (-44.15%)
» More
» Details

Insider Trades

Latest Guru Trades with PKI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 37.10
PKI's P/E(ttm) is ranked higher than
84% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 37.10 )
PKI' s 10-Year P/E(ttm) Range
Min: 5.27   Max: 3956.25
Current: 37.1

5.27
3956.25
Forward P/E 18.76
PKI's Forward P/E is ranked higher than
90% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 18.76 )
N/A
PE(NRI) 36.10
PKI's PE(NRI) is ranked higher than
86% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 36.10 )
PKI' s 10-Year PE(NRI) Range
Min: 11.52   Max: 2724
Current: 36.1

11.52
2724
P/B 2.93
PKI's P/B is ranked higher than
77% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. PKI: 2.93 )
PKI' s 10-Year P/B Range
Min: 0.88   Max: 2.93
Current: 2.93

0.88
2.93
P/S 2.72
PKI's P/S is ranked higher than
71% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. PKI: 2.72 )
PKI' s 10-Year P/S Range
Min: 0.72   Max: 2.72
Current: 2.72

0.72
2.72
PFCF 27.24
PKI's PFCF is ranked higher than
89% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 27.24 )
PKI' s 10-Year PFCF Range
Min: 7.78   Max: 92.3
Current: 27.24

7.78
92.3
POCF 24.16
PKI's POCF is ranked higher than
85% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 24.16 )
PKI' s 10-Year POCF Range
Min: 6.3   Max: 42.44
Current: 24.16

6.3
42.44
EV-to-EBIT 31.85
PKI's EV-to-EBIT is ranked higher than
80% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 31.85 )
PKI' s 10-Year EV-to-EBIT Range
Min: 9.4   Max: 57.1
Current: 31.85

9.4
57.1
PEG 3.61
PKI's PEG is ranked higher than
93% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 3.61 )
PKI' s 10-Year PEG Range
Min: 0.58   Max: 46.41
Current: 3.61

0.58
46.41
Shiller P/E 38.85
PKI's Shiller P/E is ranked higher than
88% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 38.85 )
PKI' s 10-Year Shiller P/E Range
Min: 10.11   Max: 41.14
Current: 38.85

10.11
41.14
Current Ratio 1.86
PKI's Current Ratio is ranked higher than
61% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. PKI: 1.86 )
PKI' s 10-Year Current Ratio Range
Min: 0.74   Max: 2.13
Current: 1.86

0.74
2.13
Quick Ratio 1.33
PKI's Quick Ratio is ranked higher than
56% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. PKI: 1.33 )
PKI' s 10-Year Quick Ratio Range
Min: 0.54   Max: 1.7
Current: 1.33

0.54
1.7
Days Inventory 84.04
PKI's Days Inventory is ranked higher than
78% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. PKI: 84.04 )
PKI' s 10-Year Days Inventory Range
Min: 65.31   Max: 110.09
Current: 84.04

65.31
110.09
Days Sales Outstanding 67.88
PKI's Days Sales Outstanding is ranked higher than
76% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 78.80 vs. PKI: 67.88 )
PKI' s 10-Year Days Sales Outstanding Range
Min: 57   Max: 96.02
Current: 67.88

57
96.02

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.52
PKI's Dividend Yield is ranked lower than
76% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. PKI: 0.52 )
PKI' s 10-Year Dividend Yield Range
Min: 0.52   Max: 2.43
Current: 0.52

0.52
2.43
Dividend Payout 0.19
PKI's Dividend Payout is ranked higher than
97% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 0.19 )
PKI' s 10-Year Dividend Payout Range
Min: 0.03   Max: 3.5
Current: 0.19

0.03
3.5
Yield on cost (5-Year) 0.50
PKI's Yield on cost (5-Year) is ranked lower than
85% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. PKI: 0.50 )
PKI' s 10-Year Yield on cost (5-Year) Range
Min: 0.53   Max: 2.43
Current: 0.5

0.53
2.43

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.84
PKI's Price/DCF (Projected) is ranked higher than
91% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 1.84 )
PKI' s 10-Year Price/DCF (Projected) Range
Min: 0.52   Max: 131.1
Current: 1.84

0.52
131.1
Price/Median PS Value 1.56
PKI's Price/Median PS Value is ranked higher than
60% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. PKI: 1.56 )
PKI' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 1.92
Current: 1.56

0.31
1.92
Price/Peter Lynch Fair Value 1.80
PKI's Price/Peter Lynch Fair Value is ranked higher than
96% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. PKI: 1.80 )
PKI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.74   Max: 16.36
Current: 1.8

0.74
16.36
Earnings Yield (Greenblatt) 3.10
PKI's Earnings Yield (Greenblatt) is ranked higher than
77% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. PKI: 3.10 )
PKI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.8   Max: 10.6
Current: 3.1

1.8
10.6
Forward Rate of Return (Yacktman) 22.72
PKI's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.27 vs. PKI: 22.72 )
PKI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.1   Max: 43.7
Current: 22.72

-13.1
43.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:PKN.Germany,
PerkinElmer Inc is a Massachusetts corporation, founded in 1947. The Company provides products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through its advanced technologies, solutions, and services, it addresses critical issues that help to improve the health and safety of people and their environment. The Company reports its business in two segments: Human Health and Environmental Health. Its Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, it serves both the Diagnostics and Research Markets. In Diagnostics Markets it provides early detection for genetic disorders from pre-conception to early childhood, as well as digital x-ray flat panel detectors and infectious disease testing for the diagnostics market. In the Research market, it provides suite of solutions including reagents, liquid handling and detection and imaging technologies that enable researchers to improve the drug discovery process. Its main products for Human Health applications includes DELFIA Xpress screening platform, NeoGram MS/MS AAAC in vitro diagnostic kit, NeoBase Non-derivatized MS/MS kit, Specimen Gate informatics data management solution, XRD family of amorphous silicon digital x-ray flat panel detectors, Opera high content screening system and Operetta high content imaging system, UltraVIEW VoX 3D live cell imaging system and Asset Genius, an informatics-based business intelligence solution. Its Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. Its main products Environmental Health applications includes Clarus series of gas chromatographs, Flexar series of liquid chromatography and mass spectrometry instruments and LAMBDA UV/Vis series. The Company's main brands include AlphaLISA, AlphaScreen, Asset Genius, AutoDELFIA, BACS-on-Beads, BoBs, cell::explorer, Chem3D, ChemBioOffice, ChemDraw, Columbus, Datalytix, Dexela CMOS FPDs, Elsevier's Reaxys, EnLite, Ensemble for Biology, Ensemble for Chemistry and Ensemble for QA/QC. Its customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors and government agencies. It competes with foreign and domestic organizations, which produce a comprehensive array of goods and services. The Company's operations are subject to various foreign, federal, state and local safety laws.
» More Articles for PKI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Family Dollar Stores Inc, Texas Instruments Inc, Mylan Inc, and PerkinEl Feb 08 2015 
Parkland Fuel Corporation Announces October 2014 Dividend Oct 15 2014 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
The Best Dividends on April 18, 2012 Apr 18 2012 
PerkinElmer Inc. Reports Operating Results (10-K) Mar 01 2011 
PerkinElmer Inc. Reports Operating Results (10-Q) Nov 10 2010 
PerkinElmer Inc. Reports Operating Results (10-Q) Aug 10 2010 
PerkinElmer Inc. Reports Operating Results (10-Q) May 13 2010 
PerkinElmer Inc. (PKI) Chairman, President & CEO Robert F Friel sells 150,000 Shares Dec 17 2009 
PerkinElmer Acquires Leading Diagnostics Company in China Sep 08 2009 

More From Other Websites
PerkinElmer Hits 52-Week High on Strong Q1, Favorable View - Analyst Blog May 21 2015
10-Q for PerkinElmer, Inc. (United States) May 07 2015
PerkinElmer to Present at UBS Global Healthcare Conference May 07 2015
PERKINELMER INC Files SEC form 10-Q, Quarterly Report May 05 2015
PerkinElmer to Present at Bank of America Merrill Lynch 2015 Healthcare Conference May 04 2015
PerkinElmer Beats Q1 Earnings, Misses Revenue; Guides Up - Analyst Blog May 01 2015
PerkinElmer (PKI) Earnings Report: Q1 2015 Conference Call Transcript May 01 2015
Coverage initiated on PerkinElmer by Mizuho May 01 2015
PERKINELMER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 30 2015
PerkinElmer beats 1Q profit forecasts Apr 30 2015
PerkinElmer beats 1Q profit forecasts Apr 30 2015
4:30 pm PerkinElmer beats by $0.04, misses on revs; guides FY15 EPS in-line Apr 30 2015
PerkinElmer profit tops Street forecast; lowers full-year view Apr 30 2015
PerkinElmer Announces Financial Results for the First Quarter of 2015 Apr 30 2015
Q1 2015 PerkinElmer Inc Earnings Release - After Market Close Apr 30 2015
PERKINELMER INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Apr 29 2015
Will PerkinElmer (PKI) Earnings Pull a Surprise in Q1? - Analyst Blog Apr 28 2015
PerkinElmer Board Declares Quarterly Dividend Apr 27 2015
PerkinElmer To Present at Baird 2015 Growth Stock Conference Apr 20 2015
PerkinElmer to Hold Earnings Call on Thursday, April 30, 2015 Apr 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK